|
21 Companies |
|
32 Products |
|
32 Products |
|
31 Mechanisms of Action |
|
0 Trials |
|
631 News |
|
| «123456789101112» |
- || levetiracetam / Generic mfg.
Trial primary completion date: UCB Antiepileptic Drugs (AED) Pregnancy Registry (Formerly the Keppra (clinicaltrials.gov) - Dec 23, 2015
P4, N=516, Active, not recruiting, Sponsor: UCB Pharma
Trial primary completion date: Aug 2016 --> Mar 2016
- |||| Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
Trial primary completion date, Monotherapy: Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures (clinicaltrials.gov) - Dec 12, 2015
P3, N=900, Active, not recruiting, Sponsor: Bial - Portela C S.A.
Trial primary completion date: Aug 2016 --> Mar 2016 Trial primary completion date: Nov 2015 --> Feb 2016
- phenobarbital / Generic mfg., midazolam hydrochloride / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: The Impact of Electroencephalographic (EEG) Seizure Treatment in Neonatal Encephalopathy (clinicaltrials.gov) - Dec 12, 2015
P=N/A, N=69, Completed, Sponsor: Washington University School of Medicine
Trial primary completion date: Nov 2015 --> Feb 2016 Active, not recruiting --> Completed | N=40 --> 69 | Trial primary completion date: Dec 2013 --> Dec 2015
- Trial primary completion date: Copeptin in Childhood Epilepsy (clinicaltrials.gov) - Nov 24, 2015
P=N/A, N=350, Recruiting, Sponsor: University Hospital, Basel, Switzerland
Active, not recruiting --> Completed | N=40 --> 69 | Trial primary completion date: Dec 2013 --> Dec 2015 Trial primary completion date: Oct 2015 --> Jun 2016
- Enrollment change, Trial withdrawal: TRE-NAC: Treatment Resistant Epilepsy and N-Acetyl Cysteine (clinicaltrials.gov) - Oct 22, 2015
P=N/A, N=0, Withdrawn, Sponsor: Nationwide Children's Hospital
Trial primary completion date: Oct 2015 --> Jun 2016 N=10 --> 0 | Recruiting --> Withdrawn
- ||||||| levetiracetam / Generic mfg., carbamazepine / Generic mfg.
Trial completion, Monotherapy: Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures (clinicaltrials.gov) - Oct 9, 2015
P3, N=436, Completed, Sponsor: UCB Pharma SA
N=10 --> 0 | Recruiting --> Withdrawn Active, not recruiting --> Completed
- |||| selurampanel (BGG492) / Novartis
Trial completion, Enrollment change, Trial primary completion date: Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 (clinicaltrials.gov) - Oct 7, 2015
P2, N=59, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Completed | N=77 --> 59 | Trial primary completion date: Jun 2015 --> Sep 2015
- |||| Trial primary completion date: Modified Atkins Diet Plus KetoCal for Adult Epilepsy (clinicaltrials.gov) - Oct 2, 2015
P2/3, N=80, Recruiting, Sponsor: Johns Hopkins University
Recruiting --> Completed | N=77 --> 59 | Trial primary completion date: Jun 2015 --> Sep 2015 Trial primary completion date: Mar 2017 --> Sep 2017
- |||| Trial primary completion date: Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder (clinicaltrials.gov) - Oct 1, 2015
P3, N=232, Not yet recruiting, Sponsor: INSYS Therapeutics Inc
Trial primary completion date: Mar 2017 --> Sep 2017 Trial primary completion date: Sep 2016 --> Sep 2017
- ||||| Trial initiation date, Trial primary completion date: Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome (clinicaltrials.gov) - Oct 1, 2015
P3, N=86, Not yet recruiting, Sponsor: INSYS Therapeutics Inc
Trial primary completion date: Sep 2016 --> Sep 2017 Initiation date: Aug 2015 --> Jun 2016 | Trial primary completion date: Feb 2016 --> Dec 2016
- ||||| Trial initiation date, Trial primary completion date: Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome (clinicaltrials.gov) - Oct 1, 2015
P3, N=86, Not yet recruiting, Sponsor: INSYS Therapeutics Inc
Initiation date: Aug 2015 --> Jun 2016 | Trial primary completion date: Feb 2016 --> Dec 2016 Initiation date: Aug 2015 --> Jun 2016 | Trial primary completion date: Feb 2016 --> Dec 2016
- Trial completion, Trial primary completion date: Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Chronic-Dose 4-Period Replicate Design (clinicaltrials.gov) - Oct 1, 2015
P4, N=35, Completed, Sponsor: University of Cincinnati
Initiation date: Aug 2015 --> Jun 2016 | Trial primary completion date: Feb 2016 --> Dec 2016 Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> Sep 2015
- || Trial primary completion date: Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders (clinicaltrials.gov) - Sep 30, 2015
P1/2, N=60, Recruiting, Sponsor: INSYS Therapeutics Inc
Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> Sep 2015 Trial primary completion date: Sep 2015 --> Dec 2015
- |||| Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
Trial primary completion date, Monotherapy: Eslicarbazepine Acetate Monotherapy Long Term Study (clinicaltrials.gov) - Sep 28, 2015
P3, N=348, Active, not recruiting, Sponsor: Sunovion
Trial primary completion date: Sep 2015 --> Dec 2015 Trial primary completion date: Aug 2015 --> Aug 2016
- | Enrollment closed, Trial primary completion date: HYBERNATUS: Evaluation of Therapeutic Hypothermia in Convulsive Status EPILEPTICUS in Adults in Intensive Care (clinicaltrials.gov) - Sep 25, 2015
P3, N=270, Active, not recruiting, Sponsor: Assistance Publique - H
Trial primary completion date: Aug 2015 --> Aug 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Sep 2016
- Trial primary completion date, HEOR: STEP: Enhanced Physical Activity in Children and Youth With Epilepsy (clinicaltrials.gov) - Sep 24, 2015
P=N/A, N=200, Recruiting, Sponsor: McMaster University
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Sep 2016 Trial primary completion date: Mar 2014 --> Mar 2017
- | Trial completion, Trial primary completion date: Lens Fitting Evaluation of CooperVision MyDay (clinicaltrials.gov) - Sep 22, 2015
P=N/A, N=19, Completed, Sponsor: Coopervision, Inc.
Trial primary completion date: Mar 2014 --> Mar 2017 Recruiting --> Completed | Trial primary completion date: Mar 2015 --> Jun 2015
- | bumetanide / Generic mfg.
Enrollment change: NEMO1:NEonatal Seizure Using Medication Off-patent (clinicaltrials.gov) - Sep 14, 2015
P1/2, N=14, Completed, Sponsor: Great Ormond Street Hospital for Children NHS Foundation Trust
Recruiting --> Completed | Trial primary completion date: Mar 2015 --> Jun 2015 N=49 --> 14
- Trial completion, Enrollment change: Pediatric Seizure Movement Bed Alarm (clinicaltrials.gov) - Sep 4, 2015
P=N/A, N=136, Completed, Sponsor: Le Bonheur Children's Hospital
N=49 --> 14 Enrolling by invitation --> Completed | N=200 --> 136
- |||| lacosamide / Generic mfg., fosphenytoin / Generic mfg.
Trial completion: Intravenous Lacosamide Compared With Fosphenytoin in the Treatment of Patients With Frequent Nonconvulsive Seizures (clinicaltrials.gov) - Sep 3, 2015
P2, N=74, Completed, Sponsor: Aatif Husain
Enrolling by invitation --> Completed | N=200 --> 136 Active, not recruiting --> Completed
- Trial completion: Internet Administration of the Modified Atkins Diet for Adults With Intractable Epilepsy (clinicaltrials.gov) - Sep 3, 2015
P3, N=30, Completed, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date: The Relevance of Performing Lumbar Puncture in Infants Aged 3 to 12 Months With First Episode of Febrile Convulsion (clinicaltrials.gov) - Sep 1, 2015
P=N/A, N=122, Completed, Sponsor: HaEmek Medical Center, Israel
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=300 --> 122 | Trial primary completion date: Dec 2013 --> Mar 2015
- ||| Fycompa (perampanel) / Eisai, Catalyst Pharma
Enrollment change: Pharmacokinetics, Efficacy, and Safety of Perampanel Oral Suspension on Seizure Frequency in Pediatric Subjects Maintained on One to Three Stable Antiepileptic Drugs (clinicaltrials.gov) - Aug 28, 2015
P2, N=63, Completed, Sponsor: Eisai Inc.
Active, not recruiting --> Completed | N=300 --> 122 | Trial primary completion date: Dec 2013 --> Mar 2015 N=41 --> 63
- ||||| lacosamide / Generic mfg., carbamazepine / Generic mfg.
Enrollment closed, Monotherapy: Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older (clinicaltrials.gov) - Aug 28, 2015
P3, N=551, Active, not recruiting, Sponsor: UCB BIOSCIENCES GmbH
N=41 --> 63 Recruiting --> Active, not recruiting
- ||| esomeprazole / Generic mfg.
Trial completion, Enrollment change: Drug Utilization and Safety Events Among Children Using Esomeprazole, Other Proton Pump Inhibitors or H2-receptor Antagonists (clinicaltrials.gov) - Aug 28, 2015
P=N/A, N=23470, Completed, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=11000 --> 23470
- ||| NN1213 / Novo Nordisk
Enrollment change: Pediatric Epilepsy Trial in Subjects 1-24 Months (clinicaltrials.gov) - Aug 20, 2015
P2, N=177, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed | N=11000 --> 23470 N=250 --> 177
- || Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
Trial initiation date, Trial primary completion date: A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS) (clinicaltrials.gov) - Aug 19, 2015
P=N/A, N=254, Completed, Sponsor: Eisai Inc.
N=250 --> 177 Initiation date: Apr 2013 --> Apr 2012 | Trial primary completion date: Aug 2013 --> Mar 2014
- |||| lacosamide / Generic mfg., carbamazepine / Generic mfg.
Trial primary completion date, Monotherapy: Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older (clinicaltrials.gov) - Aug 13, 2015
P3, N=527, Recruiting, Sponsor: UCB BIOSCIENCES GmbH
Initiation date: Apr 2013 --> Apr 2012 | Trial primary completion date: Aug 2013 --> Mar 2014 Trial primary completion date: Jul 2015 --> Mar 2016
- |||| Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
Trial primary completion date, Monotherapy: Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures (clinicaltrials.gov) - Aug 13, 2015
P3, N=900, Active, not recruiting, Sponsor: Bial - Portela C S.A.
Trial primary completion date: Jul 2015 --> Mar 2016 Trial primary completion date: May 2015 --> Nov 2015
- Trial completion, Trial primary completion date: Autologous Bone Marrow Stem Cells Transplantation in Patients With Temporal Lobe Epilepsy (clinicaltrials.gov) - Aug 12, 2015
P1, N=20, Completed, Sponsor: Instituto do Cerebro de Brasilia
Trial primary completion date: May 2015 --> Nov 2015 Active, not recruiting --> Completed | Trial primary completion date: Jun 2012 --> Nov 2011
- Enrollment change, Trial termination, Trial primary completion date: Carbon Dioxide (Carbogen) for the Treatment of Febrile Seizures (clinicaltrials.gov) - Aug 12, 2015
P2/3, N=96, Terminated, Sponsor: Charite University, Berlin, Germany
Active, not recruiting --> Completed | Trial primary completion date: Jun 2012 --> Nov 2011 N=288 --> 96 | Recruiting --> Terminated | Trial primary completion date: Sep 2017 --> Jun 2015; results of interim analysis (not safety relevant)
- || Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
Enrollment closed: Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA) (clinicaltrials.gov) - Aug 12, 2015
P=N/A, N=300, Active, not recruiting, Sponsor: Bial - Portela C S.A.
N=288 --> 96 | Recruiting --> Terminated | Trial primary completion date: Sep 2017 --> Jun 2015; results of interim analysis (not safety relevant) Recruiting --> Active, not recruiting
- ||| lacosamide / Generic mfg.
Trial completion, Combination therapy: VICTOS: Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat (clinicaltrials.gov) - Aug 12, 2015
P=N/A, N=315, Completed, Sponsor: UCB Pharma GmbH
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial initiation date: Evaluating the Efficacy of Magnetic Seizure Therapy in Treatment Resistant Depression. (clinicaltrials.gov) - Aug 11, 2015
P=N/A, N=200, Not yet recruiting, Sponsor: Centre for Addiction and Mental Health
Active, not recruiting --> Completed Initiation date: Nov 2014 --> Dec 2015
- Trial completion, Enrollment change: ANSeR- The Algorithm for Neonatal Seizure Recognition Study (clinicaltrials.gov) - Aug 11, 2015
P=N/A, N=240, Completed, Sponsor: University College Cork
Initiation date: Nov 2014 --> Dec 2015 Recruiting --> Completed | N=408 --> 240
- ||| Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
Trial completion: A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS) (clinicaltrials.gov) - Aug 11, 2015
P=N/A, N=254, Completed, Sponsor: Eisai Inc.
Recruiting --> Completed | N=408 --> 240 Active, not recruiting --> Completed
- | clobazam / Generic mfg.
Trial completion, Enrollment change: ESES-Clobazam: Electrical Status Epilepticus in Sleep: Response of Neuropsychological Deficits and Epileptiform Activity to Clobazam Treatment (clinicaltrials.gov) - Aug 6, 2015
P=N/A, N=17, Completed, Sponsor: Children's Hospital Boston
Active, not recruiting --> Completed Recruiting --> Completed | N=32 --> 17
- Trial primary completion date: WEPOD: Women With Epilepsy: Pregnancy Outcomes and Deliveries (clinicaltrials.gov) - Jul 15, 2015
P=N/A, N=200, Active, not recruiting, Sponsor: New York University School of Medicine
Recruiting --> Completed | N=32 --> 17 Trial primary completion date: Nov 2014 --> May 2015
- levetiracetam / Generic mfg.
Trial completion, Trial initiation date: Levetiracetam: The Anti-Convulsant of Choice for Elderly Patients With Dementia (clinicaltrials.gov) - Jun 23, 2015
P4, N=24, Completed, Sponsor: Drexel University College of Medicine
Trial primary completion date: Nov 2014 --> May 2015 Recruiting --> Completed | Initiation date: Jan 2008 --> Nov 2006
- levetiracetam / Generic mfg.
Trial completion: A Safety and Feasibility Study of Enteral LVT vs. Standard of Care for Seizure Control in Pediatric CM (clinicaltrials.gov) - Jun 22, 2015
P2, N=44, Completed, Sponsor: University of Rochester
Recruiting --> Completed | Initiation date: Jan 2008 --> Nov 2006 Recruiting --> Completed
- ||||| everolimus / Generic mfg.
Enrollment closed: EXIST-3: A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures (clinicaltrials.gov) - Jun 18, 2015
P3, N=326, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Recruiting --> Active, not recruiting
- Enrollment change, Trial termination: The Role of Serotonin in Seizures (clinicaltrials.gov) - Jun 9, 2015
P=N/A, N=46, Terminated, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting --> Active, not recruiting N=72 --> 46 | Recruiting --> Terminated
- |||| vigabatrin / Generic mfg.
Trial completion, Trial primary completion date: A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril (clinicaltrials.gov) - Jun 2, 2015
P4, N=65, Completed, Sponsor: Lundbeck LLC
N=72 --> 46 | Recruiting --> Terminated Active, not recruiting --> Completed | Trial primary completion date: Sep 2015 --> May 2015
- Trial completion, Enrollment change: Pilot Study For Hypothermia Treatment In Hyperammonemic Encephalopathy In Neonates And Very Young Infants (clinicaltrials.gov) - Jun 1, 2015
P2, N=5, Completed, Sponsor: Uta Lichter-Konecki
Active, not recruiting --> Completed | Trial primary completion date: Sep 2015 --> May 2015 Recruiting --> Completed | N=24 --> 5
- levetiracetam / Generic mfg., topiramate / Generic mfg.
Trial completion: Levetiracetam Versus Topiramate as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures (clinicaltrials.gov) - Jun 1, 2015
P4, N=343, Completed, Sponsor: UCB Korea Co. Ltd.
Recruiting --> Completed | N=24 --> 5 Active, not recruiting --> Completed
- Enrollment open: PTEpD: Preliminary Testing of a Novel Device to Detect Epileptic Seizures (clinicaltrials.gov) - May 28, 2015
P=N/A, N=126, Recruiting, Sponsor: University of Edinburgh
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- lacosamide / Generic mfg.
Trial completion, Enrollment change: Lacosamid-i.v.-Register (clinicaltrials.gov) - May 28, 2015
P=N/A, N=130, Completed, Sponsor: University of Schleswig-Holstein
Not yet recruiting --> Recruiting Recruiting --> Completed | N=200 --> 130
- ||||||| levetiracetam / Generic mfg.
Trial completion, Monotherapy: An Open Label Study of Levetiracetam Monotherapy in Patients With Newly Diagnosed Focal Epilepsy (clinicaltrials.gov) - May 21, 2015
P3, N=71, Completed, Sponsor: UCB Japan Co. Ltd.
Recruiting --> Completed | N=200 --> 130 Active, not recruiting --> Completed
- || lacosamide / Generic mfg.
Enrollment closed, Combination therapy: VICTOS: Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat (clinicaltrials.gov) - May 12, 2015
P=N/A, N=374, Active, not recruiting, Sponsor: UCB Pharma GmbH
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion: Nonconvulsive Electrotherapy: a Proof-of-concept Trial (clinicaltrials.gov) - May 6, 2015
P1, N=13, Completed, Sponsor: University of Maryland
Recruiting --> Active, not recruiting Active, not recruiting --> Completed